Skip to main content
SpringerLink
Log in

Contribution of the Microenvironment to the Pathogenesis of EBV-Positive Hodgkin and Nasal NK/T-cell Lymphomas

  • Chapter
Innate and Adaptive Immunity in the Tumor Microenvironment

Part of the book series: The Tumor Microenvironment ((TTME,volume 1))

  • 741 Accesses

Depending on the differentiation and maturation of the EBV- carrying cell the virally encoded proteins can be expressed in various assortments. The expression of these proteins determines the fate of the EBV-harboring cell. Expression of the six nuclear and three membrane-associated EBV-encoded proteins, designated Type III latency, induces cell proliferation. This occurs only in B lymphocytes. In spite of the transforming capacity of EBV, humans are virus carriers without the emergence of B-cell malignancy, because the immune system recognizes and eliminates the cells which express the growth-promoting proteins. However, immunosuppressed individuals have a high risk for EBV-induced B-cell malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rickinson AB, Kieff E (2001). Epstein-Barr virus. In: Knipe DM, Howley PM (eds). Fields virology, vol. 2, 4th edn. Lippincott Williams and Wilkins: Philadelphia, PA, pp 2575–2628.

    Google Scholar 

  2. Pope JH, Horne MK, Scott W (1968). Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3(6): 857–866.

    Article  CAS  PubMed  Google Scholar 

  3. Nilsson K, Ponten J (1975). Classification and biological nature of established human hematopoietic cell lines. Int J Cancer 15(2): 321–341.

    Article  CAS  PubMed  Google Scholar 

  4. Klein G (1994). Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77(6): 791–793.

    Article  CAS  PubMed  Google Scholar 

  5. Rowe M, Lear AL, Croom-Carter D, Davies AH, Rickinson AB (1992). Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66(1): 122–131.

    CAS  PubMed  Google Scholar 

  6. Thorley-Lawson DA (2001). Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1(1):75–82.

    Article  CAS  PubMed  Google Scholar 

  7. Hammerschmidt W, Sugden B (1989). Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340(6232): 393–397.

    Article  CAS  PubMed  Google Scholar 

  8. Kaye KM, Izumi KM, Kieff E (1993). Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 90(19): 9150–9154.

    Article  CAS  PubMed  Google Scholar 

  9. Young L, Alfieri C, Hennessy K, Evans H, O’Hara C, Anderson KC, Ritz J, Shapiro RS, Rickinson A, Kieff E, Cohen JI (1989). Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 321(16): 1080–1085.

    Article  CAS  PubMed  Google Scholar 

  10. Epstein MA, Achong BG, Barr YM (1964). Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 15: 702–703.

    Article  Google Scholar 

  11. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB (1987). Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt’s lymphoma cells. EMBO J 6(9): 2743–2751.

    CAS  PubMed  Google Scholar 

  12. Chen F, Zou JZ, di Renzo L, Winberg G, Hu LF, Klein E, Klein G, Ernberg I (1995). A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69(6): 3752–3758.

    CAS  PubMed  Google Scholar 

  13. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998). EBV persistence in memory B cells in vivo. Immunity 9(3): 395–404.

    Article  CAS  PubMed  Google Scholar 

  14. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS (1993). Epstein-Barr virus and Hodgkin’s disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177(2): 339–349.

    Article  CAS  PubMed  Google Scholar 

  15. Chiang AK, Tao Q, Srivastava G, Ho FC (1996). Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin’s disease. Int J Cancer 68(3): 285–290.

    Article  CAS  PubMed  Google Scholar 

  16. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P, Tursz T, Kallin B (1988). Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42(3): 329–338.

    Article  CAS  PubMed  Google Scholar 

  17. Klein E, Kis LL, Klein G (2007). Epstein-Barr virus infektion in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene, In Press.

    Google Scholar 

  18. Doyle MG, Catovsky D, Crawford DH (1993). Infection of leukaemic B lymphocytes by Epstein Barr virus. Leukemia 7(11): 1858–1864.

    CAS  PubMed  Google Scholar 

  19. Teramoto N, Gogolak P, Nagy N, Maeda A, Kvarnung K, Bjorkholm M, Klein E (2000). Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol 3(3): 125–136.

    CAS  PubMed  Google Scholar 

  20. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006a). IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. Blood 107(7): 2928–2935.

    Article  CAS  PubMed  Google Scholar 

  21. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006b). Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 104(1–2): 83–88.

    Article  CAS  PubMed  Google Scholar 

  22. Babcock GJ, Hochberg D, Thorley-Lawson DA (2000). The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13(3): 497–506.

    Article  CAS  PubMed  Google Scholar 

  23. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2004). Demonstration of the Burkitt’s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101(1): 239–244.

    Article  CAS  PubMed  Google Scholar 

  24. Contreras-Brodin BA, Anvret M, Imreh S, Altiok E, Klein G, Masucci MG (1991). B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. J Gen Virol 72(Pt 12): 3025–3033.

    Article  CAS  PubMed  Google Scholar 

  25. Maeda A, Bandobashi K, Nagy N, Teramoto N, Gogolak P, Pokrovskaja K, Szekely L, Bjorkholm M, Klein G, Klein E (2001). Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol 4(5): 227–237.

    CAS  PubMed  Google Scholar 

  26. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991). Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337(8737): 320–322.

    Article  CAS  PubMed  Google Scholar 

  27. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, Madsen M, Rosdahl N, Konradsen HB, Storm HH, Melbye M (2003). Characteristics of Hodgkin’s lymphoma after infectious mononucleosis. N Engl J Med 349(14): 1324–1332.

    Article  CAS  PubMed  Google Scholar 

  28. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K (1996). Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184(4): 1495–1505.

    Article  CAS  PubMed  Google Scholar 

  29. Kuppers R (2002). Molecular biology of Hodgkin’s lymphoma. Adv Cancer Res 84: 277–312.

    Article  PubMed  Google Scholar 

  30. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, Hansmann ML (1994). Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 91(23): 10962–10966.

    Article  CAS  PubMed  Google Scholar 

  31. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S (2002). Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21(32): 4908–4920.

    Article  CAS  PubMed  Google Scholar 

  32. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R (2003). Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101(4): 1505–1512.

    Article  CAS  PubMed  Google Scholar 

  33. Contreras-Brodin B, Karlsson A, Nilsson T, Rymo L, Klein G (1996). B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of the W promoter. J Gen Virol 77(Pt 6): 1159–1162.

    Article  CAS  PubMed  Google Scholar 

  34. Tierney R, Kirby H, Nagra J, Rickinson A, Bell A (2000). The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol 74(22): 10458–10467.

    Article  CAS  PubMed  Google Scholar 

  35. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B (1997). Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest 100(12): 2961–2969.

    Article  CAS  PubMed  Google Scholar 

  36. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT (1999). Mutations in the IkBa gene in Hodgkin’s disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 18(20): 3063–3070.

    Article  CAS  PubMed  Google Scholar 

  37. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, Grote W, Novo FJ, Calasanz MJ, Hansmann ML, Dyer MJ, Siebert R (2002). Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99(4): 1474–1477.

    Article  CAS  PubMed  Google Scholar 

  38. Carbone A, Gloghini A, Gruss HJ, Pinto A (1995). CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin’s disease. Am J Pathol 147(4): 912–922.

    CAS  PubMed  Google Scholar 

  39. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, Kanegae Y, Saito I, Higashihara M, Mori S, Kadin ME, Watanabe T (2002). Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21(16): 2493–2503.

    Article  CAS  PubMed  Google Scholar 

  40. van den Berg A, Visser L, Poppema S (1999). High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin’s lymphoma. Am J Pathol 154(6): 1685–1691.

    Google Scholar 

  41. Nakayama T, Hieshima K, Nagakubo D, Sato E, Nakayama M, Kawa K, Yoshie O (2004). Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol 78(4): 1665–1674.

    Article  CAS  PubMed  Google Scholar 

  42. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2004). Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103(5): 1755–1762.

    Article  CAS  PubMed  Google Scholar 

  43. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H, Ueda R (2006). Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 66(11): 5716–5722.

    Article  CAS  PubMed  Google Scholar 

  44. Dukers DF, Meij P, Vervoort MB, Vos W, Scheper RJ, Meijer CJ, Bloemena E, Middeldorp JM (2000). Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol 165(2): 663–670.

    CAS  PubMed  Google Scholar 

  45. Staratschek-Jox A, Wolf J, Diehl V (2000). Hodgkin’s disease. In: Masters JRW, Palsson BO (eds). Human cell culture, vol. 3. Kluwer: Dordrecht, pp 339–353.

    Google Scholar 

  46. Vockerodt M, Belge G, Kube D, Irsch J, Siebert R, Tesch H, Diehl V, Wolf J, Bullerdiek J, Staratschek-Jox A (2002). An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin’s lymphoma-derived cell line L591. Br J Haematol 119(3): 640–646.

    Article  CAS  PubMed  Google Scholar 

  47. Kis LL, Nishikawa J, Takahara M, Nagy N, Matskova L, Takada K, Elmberger PG, Ohlsson A, Klein G, Klein E (2005). In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 113(6): 937–945.

    Article  CAS  PubMed  Google Scholar 

  48. Baumforth KR, Flavell JR, Reynolds GM, Davies G, Pettit TR, Wei W, Morgan S, Stankovic T, Kishi Y, Arai H, Nowakova M, Pratt G, Aoki J, Wakelam MJ, Young LS, Murray PG (2005). Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106(6): 2138–2146.

    Article  CAS  PubMed  Google Scholar 

  49. Atayar C, Poppema S, Visser L, van den Berg A (2006). Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin’s lymphoma from their tonsillar counterparts. J Pathol 208(3): 423–430.

    Article  CAS  PubMed  Google Scholar 

  50. Anastasiadou E, Boccellato F, Cirone M, Kis LL, Klein E, Frati L, Faggioni A, Trivedi P (2005). Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus. Leukemia 19: 1854–1856.

    Article  CAS  PubMed  Google Scholar 

  51. Arguello M, Sgarbanti M, Hernandez E, Mamane Y, Sharma S, Servant M, Lin R, Hiscott J (2003). Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene 22: 964–973.

    Article  CAS  PubMed  Google Scholar 

  52. Babcock GJ, Thorley-Lawson DA (2000). Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci USA 97: 12250–12255.

    Article  CAS  PubMed  Google Scholar 

  53. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Eckman M, Öst A, Christensson B, Sundström C, Björkholm M, Pisa P, Masucci MG (1995). Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin’s disease. Blood 86(4): 1493–1501.

    CAS  PubMed  Google Scholar 

  54. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T (1990). Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335(8682): 128–130.

    Article  CAS  PubMed  Google Scholar 

  55. Tsuge I, Morishima T, Morita M, Kimura H, Kuzushima K, Matsuoka H (1999). Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line. Clin Exp Immunol 115(3): 385–392.

    Article  CAS  PubMed  Google Scholar 

  56. Zhang Y, Nagata H, Ikeuchi T, Mukai H, Oyoshi MK, Demachi A, Morio T, Wakiguchi H, Kimura N, Shimizu N, Yamamoto K (2003). Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 121(5): 805–814.

    Article  PubMed  Google Scholar 

  57. Takahara M, Kis LL, Nagy N, Liu A, Harabuchi Y, Klein G, Klein E (2006). Concomitant increase of LMP1 and CD25 (IL-2-receptor alpha) expression induced by IL-10 in the EBV-positive NK lines SNK6 and KAI3. Int J Cancer 119(12): 2775–2783.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Tumor and Cell Biology (MTC) Karolinska Institutet, Stockholm, 17177, Sweden

    Eva Klein & Lóránd Levente Kis

  2. Department of Otolaryngology, Asahikawa Medical College, Asahikawa, Japan

    Miki Takahara

Authors
  1. Eva Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miki Takahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lóránd Levente Kis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lautenberg Center for General and Tumor Immunology, Hebrew University—Hadassah Medical School, Jerusalem, Israel

    Eitan Yefenof

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Klein, E., Takahara, M., Kis, L.L. (2008). Contribution of the Microenvironment to the Pathogenesis of EBV-Positive Hodgkin and Nasal NK/T-cell Lymphomas. In: Yefenof, E. (eds) Innate and Adaptive Immunity in the Tumor Microenvironment. The Tumor Microenvironment, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6750-1_10

Download citation

Publish with us

Policies and ethics

Search

Navigation